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INTRODUCTION 
 
 Stroke is one of the major public health problem in all over the world. It 
plays an important role in the morbidity and mortality in the late middle age and 
in the elderly. Stroke after heart disease and cancer is the most common cause 
of death. 
 Among the neurologic disease of adult life the cerebrovascular disease 
clearly rank first in frequency and importance. At least Fifty percent of the 
neurologic disorders in a general Hospital are of this type1. 
 The burden of stroke is likely to increase substantially in the future 
because of the aging population. Apart from implementing effective stroke 
prevention programs identification of risk factors associated with stroke may 
help to ease the burden of this epidemic. 
 Stroke is a heterogenous disease. Ischaemic and haemorrhagic strokes 
are the two major types of stroke with different pathogenesis and outcome. 
 This study attempts to identify the significance of plasma Fibrinogen as 
a risk factor for stroke and also to study the correlation between the plasma 
fibrinogen levels and other major risk factors for stroke. 
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AIM OF THE STUDY  
o To study correlation between high plasma Fibrinogen and ischaemic 
stroke. 
o To study the correlation between high plasma Fibrinogen in 
cerebrovascular disease with special reference to age, sex, smoking. 
Hypertension, Diabetes mellitus and obesity. 
o To compare the results with age and sex matched control population. 
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REVIEW OF LITERATURE  
INTRODUCTION  
 Stroke is a clinical syndrome characterized by acute loss of focal brain or 
monocular function with symptoms lasting greater than 24 hours and which is 
thought to be due to inadequate cerebral or ocular blood supply. 
 The clinical manifestations of stroke are highly variable because of the 
complex anatomy of the brain and its vasculature. About 80% of all stroke are 
ischaemic 10% are due to primary intracerebral haemorrhage and 5% are due to 
subarachnoid hemorrhage in the community. 
 Cerebrovascular disease most commonly present as an acute focal 
stroke. Ischaemic arterial disease may present, particularly in elderly with a 
gradual decline in intellectual function with or without sensorymotor limb 
deficit or gait disorder. Haemorrhage from the major cerebral arteries of the 
circle of willis in to the subrachnoid space.  
 Cerebral ischaemia is caused by a reduction in blood flow that lasts 
longer than several seconds Neurologic symptoms are manifest with in seconds 
because neurons lack glycogen, so energy failure is rapid. A fall in cererbral 
blood flow to zero cause infarction within 4 to 10min, and less than 16 to 
18ml/100g tissue per min cause infarction within an hour, and blood supply 
<20ml /100g per min cause ischaemia without infarction unless prolonged for 
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several hours or days. If blood flow is quickly restored brain tissue can recover 
fully and patients symptoms are only transient; this is defined as transient 
ischaemic attack. Typically the neurologic signs and symptoms of a TIA last for 
5 to 15 mnts. But by definition must last for <24 hours. Stroke has occurred 
when the signs and symptoms last for >24hours. Focal ischaemia or infarction 
is usually caused by thrombosis  of the cerebral vessels or by emboli from a 
proximal artery or heart. Cerebral haemorrhage produces neurologic symptoms 
by producing a mass effect on neural structures or from the toxic effects of 
blood itself. 
BLOOD SUPPLY TO THE BRAIN: 
 The brain receives 20% of cardiac output, but comprises only 2% of total 
body weight. This rich blood supply is delivered by the two internal carotid and 
two vertebral arteries, which anastamose at the base of the brain to form the 
circle of Willis4. The carotid arteries supply the anterior portions of brain and 
the vertebro basilar arterial system supply the posterior portions of the brain. 
 
CAROTID ARTERIAL SYSTEM: 
 The left common carotid artery arises directly from the aorta and right 
common carotid from the innominate artery. The internal carotid artery starts at 
the carotid sinus at the bifurcation of the common carotid artery. It runs up the 
neck without any branches to reach the base of the skull and enters the carotid 
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canal of the petrous bone. It then runs through the cavernous sinus in S shaped 
curve, pierces the dura and bifurcates into anterior and middle cerebral artery. 
 
BRANCHES OF INTERNAL CAROTID ARTERY 
OPHTHALMIC ARTERY: 
 The ophthalmic artery is the first major branch of the ICA and arises in 
the cavernous sinus. It passes through the optic foraman to supply the eye and 
other structures in the orbit. 
POSTERIOR COMMUNICATING ARTERY:  
 This is the next artery to arise from the internal carotid artery. It passes 
back to join the first part of the posterior cerebral artery, so contributing to the 
circle of Willis. 
ANTERIOR CHOROIDAL ARTERY:  
 It arises from the last section of internal carotid artery and supplies optic 
tract, internal capsule, parts of basal ganglia, thalamus and optic radiation. 
ANTERIOR CEREBRAL ARTERY: 
 The anterior cerebral artery enters the interhemispheric fissure, 
anastomoses with its counter part of opposite side via anterior communicating 
artery, curves around the genu of corpus callosum and supplies the anterior and 
medial parts of the cerebral hemisphere. 
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MIDDLE CEREBRAL ARTERY 
 The middle cerebral artery enters the sylvian fissure and divides into 204 
branches which supply the lateral parts of the cerebral hemisphere. from its 
main trunk a medial and lateral group of tiny lenticulostriate arteries pass 
upwards to penetrate the base of the brain and the supply the basal ganglia and 
internal capsule. The artery supplies the whole of the motor cortox except the 
leg area. 
VERTEBRO BASILAR SYSTEM: 
VERTIBRAL ARTERY: 
 The vertebral artery arises from the proximal subclavian artery and 
ascends to pass through the transverse foramina of the second to the sixth 
cervical vertebrae, giving off small muscular branches on the way. It passes 
posteriorly around the atlas and enters the skull through the foramen magnum. 
It unites with the opposite vertebral artery on the vertebral surface of the brain 
stem to form the basilar artery. The vertebral artery gives rise to anterior and 
posterior spinal arteries, the posterior inferior cerebellar arteries and small 
penetrating branches to the medulla12. 
BASILAR ARTERY 
 The basilar artery ascends ventral to the pons to the pontomidbrain 
junction in the inter peduncluar cistern where it divides into two posterior 
cerebral arteries. Numerous small branches are given to the brain stem and 
 7
cerebellum. it gives rise to the anterior inferior cerebellar artery and superior 
cerebellar artery. 
POSTERIOR CEREBRAL ARTERY: 
 The posterior cerebral artery encircles the midbrain close to the 
oculomotor nerve at the level of tentorium and supplies the inferior part of the 
temporal lobe, and the occipital lobe. Many small branches supply the 
midbrain, thalamus, hypothalamus and geniculate bodies19. 
CIRCLE OF WILLIS: 
 The circle of Willis in the interpeduncular fossa at the base of the brain. 
It is formed by anastomosis between the two internal carotid arteries and the 
two vertebral arteries. The anterior communicating the anterior cerebral, 
internal carotid, posterior communicating, posterior cerebral and the basilar 
arteries all contribute to the circle. The circle of Willis allows blood that enters 
either by the internal carotid or the vertebral arteries to be distributed to any 
part of either cerebral hemisphere. The cortical and central branches arise from 
the circle and supply the brain substance. 
ARTERIES TO SPECIFIC BRAIN AREAS 
 Mainly the medial and lateral striate central branch of the middle 
cerebral artery supply the corpus striatum and the internal capsule; the central 
branches of the anterior cerebral artery supply the remainder of the structures. 
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 The posterior cerebral, posterior communication and basilar arteries 
supply the thalamus. 
 The posterior cerebral, superior cerebellar, and basilar arteries supply the 
mid brain.  
 The basilar and anterior, inferior and superior cerebellar arteries supply 
the pons. 
 The vertebral, anterior and posterior spinal, posterior inferior cerebellar 
and basilar arteries supply the medulla oblongata. 
VEINS OF THE BRAIN 
EXTERNAL CEREBRAL VEINS 
 The superior cerebral veins pass upward over the lateral surface of the 
cerebral hemisphere and empty into the superior sagittal sinus. The superficial 
middle cerebral veins drain the lateral surface of the cerebral hemisphere; it 
runs inferiorly in the lateral sulcus and empties into the cavernous sinus. The 
deep middle cerebral vein drains the insula and is joined by the anterior cerebral 
vein and striate veins to form the basilar vein. The basilar vein ultimately joins 
the great cerebral vein, which in turn drains into the straight sinus. 
INTERNAL CEREBRAL VEINS: 
 There are two internal veins, and the union of the thalamo striate vein 
and the choroidal vein at the interventricular foramen forms them. These two 
veins form the great cerebral vein that drains into the straight sinus. 
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EPIDEMIOLOGY 
INCIDENCE OF STROKE: 
Stroke is  world wide health problem. It makes an important contribution 
to morbidity mortality and disability in developed as well as developing 
countries24. 
 The first population based study conducted in Vellore showed an 
incidence of 13/1,00,000 population per year. The second population based 
study was carried out as a part of WHO collaborative study in Rohtak, Haryana 
between 1971-74 revealed an annual incidence of 33/1,00,000 population per 
year. The incidence of stroke rapidly increases with age. About a quarter occur 
below the age 65 and about a half below the age of 75. 
PREVALENCE OF STROKE: 
 According to the Vellore study, prevalence rate per 1 lakh population 
was 56.9 per 1 lakh. The prevalence in Eastern part of India was found to be 
160-270 per 1 lakh24. 
MORTALITY  
 Stroke is one of the leading cause of death and disability throughout the 
world. The WHO collaborative study showed that both in developed and 
developing countries, nearly one third of the stroke patients died within 3 weeks 
and 48 percent died within one year24. 
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RISK FACTORS FOR STROKE 
AGE : 
 Age is the strongest risk factor for ischaemic stroke, primary 
intracerebral haemorrhage and subarachoid haemorrhage3. 
SEX: 
 Male are associated with increased risk of stroke. 
BLOOD PRESSURE: 
 Increasing blood pressure is strongly associated with subsequent stroke 
risk with all the main pathological types23. Hypertension probably increases the 
stroke risk by increasing the extent and severity of atheroma and the prevalence 
of small vessel disease in the perforating arteries with in the brain. The 
treatment of hypertension reduces the risk of stroke. 
CIGARETTE SMOKING: 
 Smoking is a strong risk factor for subarachnoid haemorrhage and for 
ischaemic stroke, but there is less association with primary intra cerebral 
haemorrhage. Smoking has been related to the extent of carotid disease in 
patients selected for angiography. 
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BLOOD LIPIDS: 
 The relationship between blood lipids and stroke is weaker than that for 
coronary artery disease, although studies have shown a relation between 
increases serum lipoprotein (a) and stroke15. 
DIABETES MELLITUS: 
 Diabetes mellitus increases the risk of cerebrovascular disease two to 
four fold compared with non diabetics5. Strokes secondary to diabetes mellitus 
may be caused by cerebrovascular atherosclerosis, cardiac embolism and 
rheological abnormalities. Strokes in diabetics are more likely to be fatal. 
ATRIAL FIBRILLATION: 
 The most frequent potential cardiac source of embolism to the brain is 
atrial fibrillation, by virtue of clot forming in the left atrium. Both rheumatic 
and non rheumatic atrial fibrillation are associated with stroke. The risk of first 
stroke is about 5% per year in non rheumatic atrial fibrillation. 
ALCOHOL: 
 Heavy alcohol consumption is an independent risk factor for 
haemorrhagic and ischaemic stroke. But modest alcohol consumption may be 
protective for ischaemic stroke16. Confusion arises because it is difficult to 
measure alcohol consumption. 
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EXERCISE: 
 Exercise reduced blood pressure, plasma cholesterol and fibrinogen and 
the risk of non insulin dependent diabetes mellitus. Lack of exercise is 
associated with increased incidence of stroke7. 
INFECTIONS AND INFLAMMATIONS: 
 There is evidence of an association between stroke and serum C-
Reactive protein and various immediately proceeding and distant infections8. 
HOMOCYSTENIEMIA: 
 Heterozygotes for cystathionine synthetase deficiency have moderately 
raised levels of blood homocysteine with enough data linking these raised 
levels to coronary disease and stroke23. 
TRANSIENT ISCHAEMIC ATTACKS: 
 A patient with transient ischaemic attack has 5-10 times excess risk of 
getting a stroke than a person who does not. 
CARDIOVASCULAR DISEASES: 
 Angina or Myocardial infarction is clearly associated with stroke, ECG 
abnormalities reflecting hypertension and coronary artery disease are risk 
factors for stroke. Rheumatic heart disease and cardiac failure are other risk 
factors. Claudication is a high risk factor for both stroke and myocardial 
infarction, presumably reflecting atheromatous disease in other parts of 
circulation. 
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CAROTID ARTERY DISEASE: 
 When carotid artery Stenosis is greater than 75% combined transient 
ischaemic attack and stroke rate is 10.5% per year20.  
PLASMA FIBRINOGEN:  
Fibrinogen itself is a strong independent risk factor for coronary artery disease 
and stroke.  
OTHER RISK FACTORS: 
 Abdominal obesity, snoring, corneal arcus, diagonal ear lobe crease, left 
ventricular hypertrophy are other risk factors.  
CLASSIFICATION OF STROKE12,25: 
Stroke can be classified in several ways 
A) Anatomic classification: 
I. By Vascular supply 
a. Carotid 
b. Vertebro basilar 
II. By location 
a. supra tentorial 
 - lobar 
 - Ganglionic/thalamic  
b. Infratentorial 
 - Cerebellar 
 - Brainstem 
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B) PATHOPHYSIOLOGIC CLASSIFICATION 
I Ischaemic 
A) Thrombotic 
- Lacunar Storke 
- Large Vessels stroke 
B) Embolic 
- Cardioembolic 
- Artery – artery  embolic 
- Cryptogenic 
- Others 
II Haemorrhagic 
A) Intra parenchymal 
B) Subarachnoid 
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CLINICAL FEATURES OF STROKE 
TOTAL ANTEIROR CIRCULATION SYNDROME 
 A large haematoma in one cerebral hemisphere or an infarct large 
enough to affect the cortex6, basal ganglia and internal capsule causes a 
characteristic clinical syndrome of  
1. Contralateral hemiparesis with or without sensory deficit, involving the 
whole or at least two of three body areas (face, upper limb, lower limb) 
2. A homonymous visual field defect and A new higher cerebral or cortical 
dysfunction (Dysphasia, neglect, visuospatial problems etc., depending on 
cerebral dominance). Often patients are so drowsy that any cognitive and visual 
field defect have to be assumed. A large haematoma may cause midline shift, 
transtentorial herniation and coma within 24 hours, whereas these changes take 
2 or 3 days to evolve in infarct as cerebral edema develops. 
PARTIAL ANTERIOR CIRCULATION SYNDROME  
 A lobar haemorrhage or cortical infarct causes a more restricted clinical 
syndrome consisting of only two of the three components of TACS4, or just 
isolated cortical dysfunction such as dysphasia or a predominantly 
proprioceptive deficit in one limb. PACS are caused by occlusion of a branch of 
middle cerebral artery, usually as a consequence of embolism from heart or 
proximal arteries. 
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LACUNAR SYNDROME 
The four main lacunar syndromes are : 
1. Pure motor deficit:  (about 50% of lacunar cases) is a unilateral motor 
deficit involving two of three areas (face, arm, leg). There are often 
sensory symptoms but no signs. The lesion is usually in internal capsule 
or pons4. 
2. Pure sensory stroke : (about 5%) has the same distribution as pure motor 
stroke but symptoms are sensory loss. The lesion is usually in thalamus. 
3. Sensorimotor stroke (about 35%) lesion is usually in thalamus or internal 
capsule 
4. Ataxic hemiparesis (about 10%) is a combination of corticospinal and    
ipsilateral cerebellar like dysfunction affecting arm / leg and includes the 
syndrome in which there is little more than dysarthria and one clumsy 
hand. 
POSTERIOR CIRCULATION SYNDROME 
 Brainstem, cerebellar, thalamic or occipital lobe signs normally suggest 
infarction in region of vertebrobasilar circulation4. 
 A combination of brain stem and occipital lobe signs is highly 
suggestive of infarction or thromboembolism of basilar artery. 
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THALAMIC STROKE: 
 Infarction or haemorrhage of thalamus is not common. It causes 
paralysis of upward gaze, small pupils, depressed consciousness, disorientation, 
aphasia, impairment of verbal memory. 
CEREBELLAR STROKE: 
 They are uncommon. Extensive infarction or haemorrhage causes 
vertigo, nausea, horizontal nystagmus, ipsilateral and truncal ataxia, as well as 
dysarthria. There are often brain stem signs. 
BOUNDARY ZONE INFARCTS: 
 These are infarcts in the border zones between arterial territories in the 
fronto parasagittal region (anterior boundary zone). They account for a small 
percentage of strokes. Systemic hypotension which is sudden and profound as  
during cardiac arrest may cause bilateral infarcts in posterior boundary zones4. 
 
DIAGNOSTIC EVALUATION OF STROKE: 
 The next step after clinical diagnosis of stroke is to differentiate whether 
the brain lesion is due to primary intra cerebral haemorrhage or cerebral 
infarction by CT scanning or MRI. 
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 IMAGING THE BRAIN 
ISCHAEMIC STROKE : The CT appearance of cerebral infarction is time 
dependent. Although the findings may be detected within 6-8 hours of onset, 
CT may be normal up to 24 hours. 
Hyperacute infarct: 
- normal in 50-60% 
- hyperdense artery 25-50% 
- obscuration of lentiform nuclei 
Acute 
- loss of grey white matter interfaces (insular ribbon sign, obscuration 
of cortico medullary white matter border) 
- low density basal ganglia 
- sulcal effacement 
1-3 days 
 - increasing mass effect 
  - wedge shaped low density area that involves both grey and white      
    matter 
 - haemorrhagic transformation may occur. 
4-7 days 
 - gyral enhancement 
 - mass effect, edema persists 
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1-8 weeks 
  - contrast enhancement persists 
 - mass effect resolves 
months to years 
- encephalomalacic changes 
- volume loss 
- rarely calcification 
As mentioned above early findings on CT may be sudden loss of grey 
white matter contrast and effacement of adjacent subarachnoid spaces. However 
by 24 hours the abnormal low attenuating area becomes obvious. Specifically 
insular ribbon sign has been defined as an early specific sign of MCA 
infarction. The early findings on non contrast CT are the result of development 
of cytotoxic edema. Occasionally CT scan through the suprasellar may show 
hyperintense MCA indicative of thrombus within the artery. Mass effect and 
decreased attenuation increases due to combination of cytotoxic and vasogenic 
edema. Mass effect from cytotoxic edema is maximum between 3-10 days, and 
may lead to herniation. Mass effect completely resolves by 3 weeks. 
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LACUNAR INFARCTION: 
 These are secondary to arterial disease affecting the deep penetrating 
vessels of brain. These arteries may demonstrate tiny foci of sclerosis caused by 
micro atheroma or lipohyalinosis. Because of the small size CT may miss the 
infarct. 
MAGNETIC RESONANCE IMAGNING OF STROKE4: 
 Acute infarcts are identified more than and localized more distinctly on 
MRI as compared to CT. The earliest MRI findings are vascular flow related 
abnormalities. These include absence of normal flow void and slow flow with 
intravascular arterial enhancement. These signs can be detected with in minutes 
of symptom onset. Intravascular enhancement is seen nearly is there quarters of 
acute cortical infarct. Other early MRI findings include hyperintense signal on 
T2 weighted images, which may not be observed within 8 hours. On both initial 
and follow up examinations the TI weighted images are sensitive.  
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FIBRINOGEN 
The two primary sequence of fibrinogen 340,000-Dalton molecule was 
completed and the primary structure was conceived as three pairs of 
polypeptide chains named A∝, Bβ, and ϒ, composed of 610, 461, and 411 
amino acids, respectively. Each arm of the fibrinogen molecule contains single 
A∝, Bβ, and ϒ, chains from each of the three pairs of polypeptide chains.      
The centeral domain is a dimeric structure in which each dimer contains 
the three amino terminals of the individual arms. The slightly thickened amino 
terminal ends of the Aα and Bβ chains represent fibrinopeptides A and B, 
respectively, which are not present in fibrin. The dimeric halves of the central 
domain are held together by three of 11 disulfide bonds, the rest of which are 
located between the Aα and Bβ chains and in the junctions between the central 
domain and the coiled-coils. These coiled-coils are composed of the single Aα 
and Bβ and γ chains supercoiled as α-helices. Six disulfide bonds in each 
coiled-coil are responsible for the supercoil structure and for the attachment to 
the central and lateral domains in the from of disulfide rings. The basic 
structure consists of three pairs of polypeptide chains: α, β and γ, arranged in a 
mirror image9. 
 The amino acid residue orientation is such that the inside of the coiled-
coil is hydrophobic and the outside is polar. 
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 The lateral domains have a mass of 67, 200 Da each. Most of the bulk in 
each domain is represented by random folds of the γ and β lobes. There are four 
carbohydrate clusters, each 2,500 Da. Two are located on each lateral domain 
on the β chain and two on each arm in the γ chain, near the central domain. The 
Aα polar appendage, the site of primary cross-linking, is close to the carboxyl 
terminal of the γ chains. 
 Fibrinogen degradation by plasmin yielding key fibrinogen fragments is 
a physiologic process that normally takes place in vivo. However, this process 
can be reproduced in the laboratory. Plasmin digestion yields a set of core 
fragments, originally called fragments A, B, C, D and E. As determined by 
diethylaminoethyl chromatography, the fragments are labeled according to the 
order in which they emerge from the process. The intermediate products are 
fragment X and Y. the x fragment result from cleaving one of the coiled-coils 
midway between the central and lateral domain, yielding fragments D and Y.  
Future cleavage of fragment Y yields fragments D and E. 
 Plasma fibrinogen is synthesized exclusively by the hepatocyte, and the 
synthesis of the three chains is under the coordinated control of three  separate 
gene localized on chromosome 4 Subsequent to assembly of the constituent 
polypeptide chain and the addition of carbohydrate side chains, the mature 
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molecule is secreted into the circulation. Where it manifests a half life of 4 days 
and a fractional catabolic rate of 25% day. 
 Fibrinogen plays a central role in three major functional processes. 
 1. The soluble fibrinogen molecule is converted into insoluble fibrin 
during the process of blood coagulation 2. The polymerized fibrin serves as a 
template for the localized assembly and activation of the fibrinolytic system, 
which modulates fibrin deposition and clot dissolution and 3. Fibrinogen binds 
to vascular cells such as platelets where it supports platelet aggregation and to 
endothelial cells, where it participates in tissue repair. The conversion of 
fibrinogen to insoluble fibrin can be divided into three distinct phases (1) 
Enzymatic cleavage of fibrinopeptides by thrombin. (2) Fibrin polymerization, 
and (3) Fibrin stabilization via covalent cross-linking by factor XIII a. in the 
first phases, thrombin cleaves the Arg 16 Gly 17 bond of the Aα chain and the 
Arg 14 gly 15 bond of the Bβ chain, resulting in the release of two molecule of 
fibrinopeptide A and two of fibrinopeptide B per molecule of fibrinogen, results 
in the formation of fibrin monomer, the constituent chains of which are now 
referred to as the α,β and γ chains. Although the proteolytic cleavage of FP-A 
and FP-B by thrombin appears to be simultaneous, the cleavage of FP-B does 
not lead to fibrin formation under physiologic condition. The association of 
thrombin with fibrinogen is in part mediated through its catalytic site, as shown 
by nuclear magnetic resonance and x-ray crystallographic studies of thrombin 
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bound to a discrete segment of the N-terminal of the Aα chain. However, 
thrombin also binds to fibrin through a noncatalytic site called the fibrinogen 
recognition site, which binds to a locus formed by the N- terminus of the β 
chain. 
 In intact fibrinogen, the negatively charged fibrinopeptides play a role in 
maintaining the dispersion of individual fibrinogen molecules, because 
subsequent, to their cleavage by thrombin the resulting fibrin monomers 
polymerize spontaneously.  The polymerization process involves the reciprocal 
non-covalent interaction of molecular determinants in the frequent, E region of 
an adjacent fibrin monomer. The resulting dimer, which is arranged in a half-
staggered overlap, continues to grow in length by the staggered addition of 
fibrin monomers, resulting in the formation of two-stranded, half staggered 
polymer referred to as a protofibril the basic structure unit of the fibrin clot. The 
final stage of fibrin formation is characterized by the factor XIII a mediated 
formation of covalent amide bonds between the E-amino groups specific lysine 
residues and γ CONH2 groups of certain glutamine residues. These covalent 
bonds are first formed at the DD contact between the γ chains of two molecules. 
The dimerization of the γ chain formed by bridges between lys 406 of one γ 
chain and glu 398/399 of another is then followed by progressive covalent 
cross-linking of multiple-chains. Cross linking at branch points also produces D 
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trimers (or) D-tetramers. As a result of this covalent to both mechanical 
disruption and dissolution by plasmin. 
 In addition to plasma fibrinogen, the circulating blood contains a very 
small pool of fibrinogen, which is present with in the platelet α granules. Some 
have shown that the fibrinogen is synthesized by the megakaryocyte, but more 
investigations demonstrated that both megakaryocyte and platelets are capable 
of internalizing fibrinogen from plasma via a process mediated by glycoprotein 
II b/III a. platelet fibrinogen lacks γ chain. The discrepancy between the 
molecular and functional properties of plasma and platelet fibrinogen is depend 
on the ability of the platelet megakaryocyte to internalize the abnormal 
fibrinogen. Platelet fibrinogen is secreted after stimulation and plays a role in 
supporting haemostasis. 
HYPERFINRINOGENEMIA 
 Plasma fibrinogen levels increase significantly with age, with life style 
habits such as smoking, and in certain pathologic conditions such as 
hypertension, obesity, and diabetes mellitus. However even, among normal 
individuals the plasma fibrinogen concentration varies and, although the exact 
regulatory mechanism is unknown, recent studies indicate that fibrinogen levels 
may be genetically controlled. For example high plasma fibrinogen 
concentrations have been observed in normal individuals exhibiting a special 
nucleotide sequence polymorphism at the 5’ untranslated region of the Bβchain 
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seems to be a rate limiting step in fibrnogen biosynthesis, increased trancription 
of this gene is likely to result in present in only a minority of the population. By 
contrast, in most individuals fibrinogen behaves as an acute phase reactant 
protein. Therefore its concentration is sensitive to inflammatory responses. In 
this process the release of IL – 6 by macrophages leads to an increase in 
transcription of Bβ gene, resulting in elevated levels of fibrinogen. It is also 
possible that a genetic polymorphism distinct from that in the 5’ untranslated 
region described above and located within the IL-6 responsive element may 
play an important role in setting the level of fibrinogen in different individuals. 
 The concentration of plasma fibrinogen has important clinical 
implication, as indicated by several studies demonstrating that 
hyperfibrinogenemia is an independent risk factor in stroke and in IHD. Plasma 
fibrinogen concentration in the upperthird of the population increased the risk 
of CVD threefold as compared with those in the lower of fibrinogen such as 1 
standard deviation (SD)  ( 0.6 mg/ml) above the mean markedly increase the 
risk of CVD. When other risk factors for CVD stroke such as high BP, serum 
cholesterol, age, diabetes, and smoking were considered, high levels of 
fibrinogen were still evident as an important risk factor. 
Plasma fibrinogen has been implicated in atherogenesis and in arterial 
thrombus formation. A number of epidemiologic studies have shown a 
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substantial and significant impact of fibrinogen on cardiovascular disease 
incidence including stroke. 
 Level of fibrinogen measured at the10th biannual examination in 
formation was also significantly related to incidence of vascular disease 
including stroke.  
Fibrinogen was also positively associated with most of the major risk 
factors for stroke including age, hypertension, obesity and diabetes. There of 
fibrinogen and other clotting factors will yield important clues into the 
pathogenesis of atherosclerotic vascular disease. 
Pai Mahes C, Chandrasekhara P. et al done a  study to identify the 
significance of plasma fibrinogen as a risk factor for ischaemic stroke and also 
to study the correlation between plasma fibrinogen levels and other major risk 
factor to stroke. This study includes fifty patients with features of 
cerebrovascular accident., proved to have cerebral infarction. CT scan were 
taken for all cases were compared with fifty controls with respect to age and 
sex. Plasma fibrinogen was estimated in all cases and controls. This study 
shows significant statistical difference in cases and controls. Fibrinogen was 
high among the males and increases with age. It was significantly higher in 
diabetics when compared to non diabetics. It was also higher in hypertensive 
and smokers. Hyperfibrinogenemia is associated with stroke recurrence and 
TIA21. 
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Lee , Lowe GD, M wood word Et all provides the relations of plasma 
fibrinogen to family History of premature heart disease, personal History  of 
hypertension, diabetes, stroke and coronary heart disease. This large 
populations study found that plasma fibrinogen is not only a risk factor for 
coronary heart disease and stroke but it is also raised with family history of 
premature heart disease and with personel history of hypertension diabetes and 
obesity18. 
Aizhong gu and K. Sree Kumarannair found the association between 
atherosclerotic disease and fibrinogen levels, plasma concentrations of 
fibrinogen increased with age. This study also demonstrated that the increased 
levels of fibrinogen represent a slower rate of disposal of fibrinogen rather than 
increased production rate2. 
Graziella Bruno, et al studied the distribution of plasma fibrinogen levels 
and the prevalence of hyper fibrinogenemia in Type 2DM. Patients with type 2 
diabetes mellitus had a high prevalence of hyper fibrinogenemia. Levels 
slightly differed men and women. In men fibrinogen increased with age11. 
Hazra B, Sengupta N, Saha SK et al in their study on slusrna fibrinogen 
in stroke, reveled that the elevated plasma fibrinogen may be an important risk 
factor for the thrombotic ischaemic stroke13. 
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 Koenig et al provides an overview of recently accumulated evidence on 
the pathogenetic role of fibrinogen in various vascular beds, and tries to 
elucidate determinants for patients susceptibility so that subgroups at particular 
risk of severe clinical complications can be characterized more accurately17. 
 Based on the considerable elevated risk of cardiovascular and 
cerebrovascular disease complications associated with increased levels of 
plasma fibrinogen, the potential value of lowering in the primary or secondary 
prevention of atherosclerotic disease is now recognized as an important topic 
for consideration17. 
Qizibash – N et al has been identified in two prospective observational 
studies. The importance of fibrinogen. The relationship has been followed to be 
independent of other haemostatic and haemorrheological factor (Eg. Von 
willebrand factor, Tissue plasminogen activator and packed cell volume). 
Fibrinogen should be considered a risk factor for lschaemic stroke and included 
in the assessment of Individual risk factors. Therefore, after blood pressure, 
fibrinogen is the most important potentilly treatable risk factor for ischaemic 
stroke. There are several mechanisms whereby fibrinogen could promote 
atherothromboembolism. Thrombosis through a hyper coagulable state, the 
acceleration of atherosclerosis, or the reduction of blood flow. Due to high 
blood or plasma viscosity. The mechanism, however, is unlikely to be mediated 
through high blood viscosity per se as secondary erythrocytosis (Another major 
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determinant of blood viscosity) has not consistently    been found to be a risk 
factor for stroke. Fibrinogen should be considered a risk fator for ischaemic 
stroke and included in the assessment of individual risk factors22. 
Thavaraj V; Behari-M; Prasad K, et al carried out blood viscosity studies 
were in 14 patients with acute stroke, 8 with cerebral infarction, 6 with cerebral 
haemorrhage and in thirteen controls. We observed a statistically significant 
higher values of plasma, Red cell and whole viscosity in patients with acute 
stroke than in normal controls. Plasma fibrinogen levels were statistically 
higher (P<0.01) in patients than in normal controls. The platelet aggregation 
was increased in two young adults with acute stroke. The results suggest that 
the haemorrheological factors play an important role in the pathophysiology of 
stroke patients26.  
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MATERIALS AND METHODS 
Setting: 
 This study was carried out in the Department of medicine, Madurai 
Medical College and Government Rajaji Hospital, Madurai.  
Period of Study: 
 1 year from Jun 2005 to May 2006.  
Design of study: 
 This is a prospective study of consecutive patients with ischemic stroke 
admitted to Government Rajaji Hospital, Madurai.  
Sample Size:  
 50 patients with ischemic stroke admitted in the Department of Medicine 
Government Rajaji Hospital, Madurai, and 50 controls of age and sex match  
were taken. 
Inclusion Criteria: 
 All patients those who have presented with definitive signs of 
neurological deficit with CT proved ischemic stroke.  
Exclusion criteria: 
1. Individual with acute infection and inflammatory episode  
2. Patients with valvular heart disease 
3. Patients with clot in the left ventricular cavity  
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4. Patients with absent peripheral pulses 
5. Pregnancy and Puerperium 
6. Women on oral contraceptive pills 
7. Moderate and severe Alcoholism. 
METHODS: 
HISTORY 
 Name, Age, Sex of each patient was noted. The presenting complaint of 
neurological deficit and the mode of onset was evaluated. Special emphasis was 
made to obtain the H/o head ache, H/o loss of consciousness, H/o Seizures, H/o 
Trauma to the head, H/o malignancy and H/o Oral contraceptive pills in 
females. 
 Past history of TIA, hypertension, diabetes mellitus, were carefully 
sought. Enquiry about alcoholism, smoking, pregnancy or recent delivery was 
done. Any similar illness in the family was noted. 
GENERAL EXAMINATION  
 In general examination apart from the routine observations, special 
emphasis was made to identify the BMI,  corneal arcus, status of peripheral 
vessels and carotid bruit. 
CENTRAL NERVOUS SYSTEM EXAMINATION  
 Tests for higher cortical functions were performed in patients those who 
were conscious. Examination for cranial nerve dysfunction was done in detail in 
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patients who were conscious. Efforts were made to identify the cranial nerve 
dysfunction in all patients. 
 Examination of spinomotor system was done meticulously to identify the 
neurological deficit as complete or partial. Sensory system examination was 
done and hemianaesthesia if present was identified by clinical examination.  
 Cerebellar dysfunction if present was elicited in detail. Bladder and 
bowel involvement was noted down. Signs of meningial irritation, and 
increased intracranial tension, was elicited and noted down. Optic fundus was 
visualized in all cases to identify, diabetic retinopathy, hypertensive 
retinopathy, and papilloedema.  
 Other systems were also examined in detail. 
INVESTIGATIONS: 
 Basic investigations such as Hb, Routine blood cell count, urine analysis 
for albumin, sugar deposit, blood sugar, urea serum creatinine and serum 
electrolytes total cholesterol were done. 
Plasma fibrinogen, electrocardiography, echocardiography and CT scan 
of brain were done. 
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METHOD OF ASSAYING FIBRINOGEN IN PLASMA: 
 Normal plasma fibrinogen level ranges from 190 to 400mgs/ 100ml of 
plasma, however the level more than 250mgs% can be considered as a risk 
factor as far as cerebrovascular disease is concerned.  
 (Rapid Turbidometric method) 
Principle: When sodium sulphite is added to plasma, it forms a turbidity 
as it has specific affinity towards plasma fibrinogen. This fibrinogen can be 
read in quantitative term by comparing it with artificial Protein standards: 
Required Reagents 
1. 0.2ml of heparinized (or) Oxalated plasma  
2. 3.8 of 12.5% sodium sulphite 
(12.5 gm of anhydrous Na2 So3/100ml in water) solution 
Test Method 
 Wash 0.2ml of heparinized (or) Oxalated plasma into 3.8ml of freshly 
prepared 12.5% sodium sulphite solution. Shake, allow to stand for exactly 
10min., shack again and read the turbidity by comparison with artificial protein 
standards. 
 A control with serum should be setup in case of deterioration of the 
sodium suphite; this should give no turbidity. The sodium suphite solution must 
be prepared from the dry salt immediately before use. 
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 Fibrinogen = value of matching tube x 10 c.i.e. if the test matches the 
tube labeled equivalent to 10mg per 100 ml then the fibrinogen = 100mg / 
100ml. 
 
STATISTICAL ANALYSIS: 
 The figures collected were posted in a master chart. Statistical analysis 
was done using epidemiological package 2002 developed for WHO. Kruskall 
Wallis ‘Chi’ square test was used to find significance. A ‘P’ value less than 
0.05 is taken to indicate significant difference among the variables.  
 
 
 
 
 
 
 
 
 
 
 
 
 36
OBSERVATION AND RESULTS  
Table - 1 
INCIDENCE IN RELATION TO AGE 
 
AGE NO. OF PATIENTS  PERCENTAGE M/F 
31-40 
41-50 
51-60 
61-70 
>71 
4 
11 
14 
17 
4 
8% 
22% 
28% 
34% 
8% 
3/1 
9/2 
11/3 
11/6 
4/0 
 
 In the age group of 31 to 40 there Were 8% of which 3 are male and 1 
female. There were 11 patients in age group of 41 to 50 comprising 22% of 
which 9 males and 2 females. 
 In the age group of 51 to 60 there were 11 males and 6 females 
comprising 28% of the total 7 patients were in the age group of 61 to 70 and 4 
patients in the age group of greater than 71. 
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Table -2  
 
INCIDENCE WITH RELATION TO SEX  
 
Sex NO. OF PATIENTS PERCENTAGE 
Male 
 
Female 
38 
 
12 
76% 
 
24% 
 
Among the 50 patients  76% of the patients were  Male 24% were female  
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Table - 3 
 
SIGNIFICANT HISTORY 
 
HISTORY NO. OF PATIENTS PERCENTAGE 
T1A 
Diabetes  
Hypertension 
Smoking 
IHD 
7 
30 
19 
27 
11 
14% 
60% 
38% 
54% 
22% 
 
 In our study 60% of the patients were associated with diabetes mellitus  
  54% patients were smokers. 
 38% of the patients associated with hypertension  
22% of the patients had IHD and 14% of the patients had H/o TIA  
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Table -4 
IMPORTANT SYMPTOMS 
SYMPTOMS NO. OF PATIENTS PERCENTAGE 
Head ache 
Loss of consciousness 
Seizures 
Trauma 
Vertigo 
Vomiting 
Diplopia 
Dysphasia 
Facial deviation 
Dysphagia 
20 
15 
6 
- 
3 
12 
3 
29 
47 
4 
40% 
30% 
12% 
6% 
24% 
- 
6% 
58% 
94% 
8% 
 
  In our study 94% of the patients had Facial Deviation, 58% of the 
patients had Dysphasia, 40% of the patients had Head ache and 30% of the 
patients presented with loss of consciousness  
 24% of the patients complaint vomiting and 12% of the patients had 
Seizures. 8% of the patients had Dysphagia, 6% of the patients had Diplopia 
and 6% with vertigo  
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Table - 5 
IMPORTANT SIGNS 
SIGNS NO. OF PATIENTS PERCENTAGE 
Carotid bruit 
Cranial nerve dysfunction 
Other than UMN type of VII 
nerve 
Hemianaesthesia 
Hemianopia 
Bladder dys function 
Signs of increased ICT 
Papilloedema 
2 
 
 
6 
3 
1 
10 
6 
6 
4% 
 
 
12% 
6% 
2% 
20% 
12% 
12% 
  
 In our study 20% of the patients had Bladder dysfunction. 
 12% of the patients had Signs of increased ICT.  
12% of the patients had Papilloedema.  
12% of the patients had cranial nerve dysfunction other than UMN type 
of seventh nerve palsy.    
6% of the patients had Hemianaesthesia. 
2% of the patients had Hemianopia 
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Table - 6 
AGE AND PLASMA FIBRINOGEN 
Cases Controls Age Group 
Mean SD Mean SD 
31-40 
41-50 
51-60 
61-70 
>70 
345 
334.5 
382.2 
414.7 
440 
128.7 
79.5 
149.4 
134.6 
84.8 
187.5 
219.1 
277.9 
276.8 
311.3 
34.8 
60.8 
701.7 
83 
43.3 
p Value 0.4071 
 
0.0128 
 
Our study shows there was significant difference in plasma fibrinogen 
level between different age group in both cases and control the relationship 
between age and plasma fibrinogen level was statistically not significant in 
cases(P= 0.4071)and significant in controls (P= 0.0128)  
 
 
 
 42
 
 
Table -7 
SEX AND PLASMA FIBRINOGEN 
Cases Controls Sex 
Mean SD Mean SD 
Male 
Female 
384.5 
384.2 
125 
134.1 
275 
200 
75.2 
53.9 
p Value 0.9185  0.0066  
 
 In our study there was no statistically difference between sex and plasma 
fibrinogen level of cases (P= 0.9185) while controls showed statistically 
significant difference (P= 0.0066)   
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Table - 8 
 
DM AND PLASMA FIBRINOGEN 
 
Cases Controls DM 
Mean SD Mean SD 
Diabetes 
Non Diabetes 
435.5 
307.8 
128.3 
73.7 
320.5 
212.5 
60.1 
47.6 
p Value 0.0004  0.0001 
 
 In our study there was a statistically significant difference between 
diabetics and non diabetics in both cases (P= 0.0004) and in controls (P= 
0.0001) 
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Table  - 9 
PLASMA FIBRINOGEN IN DM OF CASES VS CONTROL 
PLASMA FIBRINOGEN DM 
Mean SD 
CASES 
CONTROLS 
435.5 
32.5 
128.3 
60.1 
p Value P 0.0006 
 
 This table shows there was a statistically significant difference in plasma 
fibrinogen in diabetics of cases and controls (P= 0.0006)  
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Table  - 10 
 
HT AND PLASMA FIBRINOGEN 
 
Cases Controls HT 
Mean SD Mean SD 
HT 
Non HT 
431.3 
355.7 
123.5 
120.3 
300.6 
239.1 
81.6 
64.1 
p Value 0.0324  0.0184 
 
 There was a statistically significant difference in plasma level in 
hypertensives and non hypertensives of both cases (P= 0.0324) and controls (P= 
0.0184) 
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Table  - 11  
PLASMA FIBRINOGEN IN HT CASES Vs CONTROLS 
Plasma fibrinogen  Hypertension  
Mean SD 
Cases 
Controls  
431.3 
300.6 
123.5 
81.6 
p Value 0.0012 
 
 In this study plasma fibrinogen was statistically significant difference in 
hypertensive cases and hypertensive controls (P= 0.0012) 
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Table - 12 
SMOKING AND PLASMA FIBRINOGEN 
Cases Controls Smoking 
Mean SD Mean SD 
Smokers 
Non Smokers 
338.9 
313.2 
118.4 
112.8 
283.9 
265.9 
83.4 
64.8 
p Value 0.438 
 
0.6807 
 
 There was no statistically significant difference in plasma fibrinogen 
levels in  smoker and nonsmokers  of both cases (P= 0.438) in controls  
(P= 0.6807) 
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Table 13 
PLASMA FIBRINOGEN IN SMOKERS CASES Vs CONTROLS 
PLASMA FIBRINOGEN GROUP 
Mean SD 
Cases 
Controls 
338 
283 
118.4 
83.4 
p Value 0.0064 
  
 Plasma fibrinogen level was statistically significant difference in 
smokers of cases and controls (P= 0.0064) 
 
 
 
 
 
 
 49
 
 
Table  - 14 
CHOLESTEROL AND PLASMA FIBRINOGEN 
Cases Controls Cholesterol  
Mean SD Mean SD 
<200mg/dl 
>200mg/dl 
349.5 
441.3 
120.3 
116.1 
242.1 
370 
63 
50.7 
p Value 0.0053 0.0002 
 
 In our study there was a statistically significant difference in plasma 
fibrinogen level in patients with hypercholesterolemia and normal  cholesterol 
level of both cases (P=0.0053) and controls (P=  0.0002)  
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Table 15  
PLASMA FIBRINOGEN IN HYPERCHOLESTROLEMIA 
CASES Vs CONTROLS 
Plasma Fibrinogen  GROUP 
Mean SD 
Cases 
Controls 
441.3 
370 
116.1 
50.7 
p Value 0.1834 
 
 In our study there was no statistically significant difference in 
hypercholesterolemia of cases and controls (P=0.1834) 
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Table - 16 
BMI AND PLASMA FIBRINOGEN 
Cases Controls BMI 
Mean SD Mean  SD 
<23 246.2 76.5 236.2 59.2 
>23 386.9 113.9 310.7 83.5 
P value  0.0001 0.0024 
 
 There was a statistically significant difference in obesity and plasma 
fibrinogen level in both cases (P= 0.0001) in controls (P=0.0024) 
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Table - 17  
 PLASMA FIBRINOGEN AND OBESITY 
CASES Vs CONTROLS 
Plasma Fibrinogen GROUP 
Means SD 
Cases 419.1 110.2 
Controls 310.7 83.5 
P value  0.0027 
 
 There was a statistically significant difference in cases and controls with 
increased BMI (P=0.0027) 
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Table 18 
PLASMA FIBRINOGEN IN CASES Vs  CONTROL 
Plasma Fibrinogen  Group 
Mean SD 
Cases 384.4 125.8 
Controls 
 
260 
 
75.5 
p Value 0.0001  
 
 In our study there was a statistically significant difference in plasma  
fibrinogen level of cases and controls  (P= 0.0001) 
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DISCUSSION 
 In the study population of 50 patients, the age of patients ranged from 33 
years to 81 years. There were 4 patients in age group of 31 to 40 includes 3 
male and 1 female. There were 11 patients in 41 to 50 age group includes 9 
males and 2 females. In the age group of 51 – 60 there were 14 patients of 
which 11 were male 3 were female. 17patients in the age group of 61-70 of 
which 11 were males and 6 were females and 4 male patients in the age group 
of more than 71. 
 In those 50 patients 38 were male 12 were female patients indicating a 
male predominance  
The incidence of major vascular risk factors was analysed, diabetes 
mellitus was found in 60% of the patients hypertension was found in 38% of the 
patients. Smoking was present in 54% of the patients. History of coronary 
artery disease was present in 22% of the patients previous history of TIA was 
present in 14% of patients hypercholesterolemia found in 38% of the patients. 
BMI more than 23 found in 38 patients. 
 Analysis of the signs and symptoms of the patients shows facial 
deviation present in 94% of patients. head ache in 20% of the patients. Loss of 
consciousness present in 22% of the patients. 12% of the patients had seizures. 
Vomiting present in 24% of the patients. 
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 Plasma fibrinogen level was significantly increased with age advance in 
the control group not in the cases. Male has high plasma fibrinogen value than 
female in the control group  
 Plasma fibrinogen level was increased in hypertension, diabetes, obesity 
and hyperchloesterolemia. This is correlate with Pai Mahesh C. et al and Lee et 
al study. But there is no significant difference in smokers and non smokers. 
When plasma fibrinogen levels in stroke group with one risk factor 
compared with control group with same risk factor a statistically difference 
found in diabetes, hypertension smokers and obese patients. This is correlate 
with Pai Mahesh C. et al study. But there is no significant difference in patients 
with hypercholesterolemia. 
 A statistically significant raise in plasma fibrinogen level was observed 
in the stroke patients compared to that in the control group. This is correlates 
with Pai Mahesh C. et al and Harza B et al study  
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CONCLUSION 
• This study shows the association of elevated level of plasma fibrinogen 
in stroke patients compared to the age and sex matched control 
population.  
• Plasma fibrinogen level was significantly elevated in other major risk 
factor for stroke like hypertension, diabetes, obesity and 
hypercloesterolemia.  
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ABBREVIATION 
  
 
 ACA  - Anterior Cerebral Artery  
 BMI  - Body Mass index 
 CT  - Computerised Tomography 
 CVA  - Cerebrovascular Accident    
 CVD  - Cerebrovascular Disease   
 DM  - Diabetes Mellitus 
 FPA  - Fibrinopeptide - A 
 FPB  - Fibrinopeptide -B 
 HT  - Hypertension 
 IHD  - Ischaemic heart disease  
 MCA  - Middle cerebral artery 
 MRI  - Magnetic Resonance Imaging 
 P  - ‘P’ Value 
 PACS  - Partial Anterior Circulation Syndrome 
 PCA  - Posterior cerebral artery 
 SD  - Standard Deviation 
 TACS  - Total Anterior Circulation Syndrome 
 TIA  - Transient Ischaemic attack 
 WHO  - World health organization  
PROFORMA 
NAME:    AGE:   SEX: 
I.P.NO:    OCCUPATION   
ADDRESS 
PRESENT ILLNESS: 
Time and Mode of onset 
H/O Head Ache  H/O LOC  H/O Seizures 
H/O Trauma    H/O Vertigo  H/O Diplopia 
H/O Vomiting  H/O Dysphasia H/O Dysphagia 
PAST ILLNESS 
H/O TIA   H/O Diabetes  H/O Hypertension 
H/O Tuberculosis  H/O Smoking H/O Angina / IHD 
GENERAL EXAMINATION  
Anaemia  Obesity   Corneal Arcus 
Carotid Bruit  Pulse     BP 
Peripheral Vessels  Fundus. 
CNS 
Higher Function 
Cranial Nerves 
SPINOMOTOR  SYSTEM  
Hemiplegia / Hemiparesis  
SENSORY SYSTEM 
Hemianaesthisa 
CEREBELLUM  
SPINE AND CRANIUM 
OTHER SYSTEMS EXAMINATION  
INVESTIGATIONS: 
Urine   Albumin  Sugar   Deposit 
Blood   Sugar   Urea    
Serum   Cholesterol  ESR 
Plasma Fibrinogen 
ECG 12 Leads 
Echo cardiography 
 
CT Scan Brain. 
 
MASTER CHART  CASES 
 
S.No. 
 
Name GROUP Age Sex Smoking DM HT Cholesterol BMI 
Plasma 
Fibrinogen 
1 Venugobal Cases 48 Male Yes No No 156 26.71 290 
2 Ponnaiyan Cases 46 Male Yes Yes No 270 25.36 370 
3 Chithambram Cases 39 Male No Yes No 255 28.2 380 
4 Murugan Cases 33 Male Yes Yes No 225 24.2 510 
5 Saraswathi Cases 42 Female No Yes Yes 242 24.01 490 
6 Vasnatha Cases 35 Female No No Yes 175 25.71 270 
7 Muthu Cases 38 Male Yes No No 180 21 245 
8 Sundaram Cases 45 Male Yes No No 161 22.4 245 
9 Shanthakumar Cases 42 Male No Yes No 210 21.4 275 
10 Velathal Cases 47 Female No Yes Yes 230 23.04 410 
11 Andiappan Cases 55 Male Yes No No 110 22.7 260 
12 Duraipandi Cases 61 Male Yes No No 210 26.71 320 
13 Rajalakshmi Cases 61 Female No Yes No 189 21.9 245 
14 Alaharsamy Cases 58 Male Yes No No 146 23.04 280 
15 Chellammal Cases 63 Female No Yes Yes 210 28.8 270 
16 Pitchai Cases 61 Male Yes No No 156 24.01 295 
17 Duraisamy Cases 62 Male No Yes Yes 273 24.01 495 
18 Kuppusamy Cases 75 Male No No No 180 23.2 345 
19 Pandi Cases 56 Male Yes Yes No 145 23.01 430 
20 Manogaran Cases 46 Male Yes No No 175 24.01 355 
21 Mahalingam Cases 48 Male No No Yes 100 25.75 350 
22 Muthammal Cases 61 Female No Yes No 166 24.01 445 
23 Pandian Cases 66 Male Yes Yes Yes 156 26.71 295 
24 Panchu Cases 81 Male No Yes Yes 225 28.2 550 
25 Subbyah Cases 73 Male Yes No Yes 166 24.01 445 
26 Raman Cases 72 Male Yes Yes No 136 24.01 420 
S.No. 
 
Name GROUP Age Sex Smoking DM HT Cholesterol BMI 
Plasma 
Fibrinogen 
27 Seemaisamy Cases 62 Male No Yes Yes 216 24.01 295 
28 Kasi Cases 55 Male No No No 105 22 236 
29 Palaniappan Cases 51 Male Yes No No 225 26.71 360 
30 Valliammal Cases 60 Female No Yes No 180 22.4 620 
31 Panchavarnam Cases 56 Female No Yes No 180 24.01 345 
32 Kumarayi Cases 65 Female No Yes Yes 246 27.48 320 
33 Muthuvel Cases 55 Male Yes Yes Yes 266 24.01 505 
34 Gunasekaran Cases 56 Male Yes Yes Yes 175 24.01 645 
35 Ismail Cases 62 Male No Yes No 275 24.01 630 
36 Maruthai Cases 53 Female No Yes Yes 140 24.01 420 
37 Veeranan Cases 62 Male Yes No No 108 20.8 255 
38 Periaveeran Cases 56 Male Yes Yes Yes 210 30.48 620 
39 Rahimabdulla Cases 51 Male Yes Yes Yes 260 26.71 550 
40 Kandasamy Cases 49 Male Yes No No 190 24.71 395 
41 Kumarasamy Cases 48 Male Yes No No 155 21.3 250 
42 Krisha aayar Cases 64 Male Yes Yes No 256 24.01 490 
43 Thangavel Cases 56 Male No Yes Yes 140 28.2 260 
44 Seenithevar Cases 63 Male Yes Yes Yes 165 28.04 460 
45 Muthurajan Cases 65 Male No No No 166 23.03 490 
46 Swaminathan Cases 52 Male Yes No No 165 20.5 245 
47 Balakrishnan Cases 65 Male Yes Yes Yes 256 27.29 545 
48 Rakkayi Cases 65 Female No Yes No 146 32.29 580 
49 Perumal samy Cases 45 Male Yes No No 175 20.9 250 
50 Ramayammal Cases 53 Female No Yes No 180 20.4 195 
 
CONTROLS 
 
S.No. 
 
Name GROUP Age Sex Smoking DM HT Cholesterol BMI 
Plasma 
Fibrinogen 
51 Kandasamy Control 49 Male Yes Yes No 226 20.37 355 
52 Pandi Control 45 Male No No Yes 136 23.2 155 
53 Devi Control 63 Female Yes No No 162 21.09 170 
54 Singaram Control 62 Male Yes No No 116 20.37 270 
55 Kesavan Control 55 Male Yes No No 96 20.27 205 
56 Susai Control 56 Male Yes No No 136 19.5 255 
57 Veeran Control 51 Male Yes No Yes 166 22.4 265 
58 Arasi Control 65 Female No Yes Yes 186 22.4 235 
59 Devathasan Control 75 Male No Yes No 160 31.88 315 
60 Kamaraj Control 71 Male Yes Yes No 156 26.71 370 
61 Asaithambi Control 51 Male Yes No Yes 186 24.01 336 
62 Kalayani Control 38 Male Yes No No 120 22.4 155 
63 Rajendran Control 33 Male Yes No No 125 20.27 220 
64 Chinnasamy Control 47 Male No Yes Yes 185 20.27 290 
65 Raja Control 65 Male Yes Yes Yes 246 30.48 410 
66 Ramaiya Control 56 Male Yes Yes No 185 21.64 370 
67 Paramasivam Control 62 Male Yes No No 166 20.27 255 
68 Velusamy Control 63 Male No Yes Yes 196 24.01 365 
69 Chellammal Control 66 Female No No No 166 18.9 155 
70 Ponnambalam Control 80 Male No Yes No 146 24.01 290 
71 Narayanan Control 55 Male No Yes No 146 20.4 275 
72 Mohaiddin Control 46 Male No No No 106 20.27 155 
73 Arumugam Control 46 Male No No Yes 200 22.4 215 
74 Gurusamy Control 61 Male Yes No No 96 18.9 240 
75 Karuppusamy Control 62 Male No No Yes 116 30.48 240 
76 Rangasamy Control 65 Male No Yes No 144 31.88 305 
S.No. 
 
Name GROUP Age Sex Smoking DM HT Cholesterol BMI 
Plasma 
Fibrinogen 
77 Nachiyappan Control 63 Male Yes Yes Yes 240 28.2 405 
78 Periyasamy Control 55 Male No Yes Yes 210 22.4 365 
79 Ochammal Control 42 Female No Yes Yes 180 22.4 230 
80 Rasathi Control 60 Female No No Yes 216 22.4 265 
81 Jeevaraj Control 56 Male Yes Yes Yes 260 26.71 390 
82 Pandiyammal Control 56 Female Yes No No 165 19.46 150 
83 Muniyandi Control 48 Male Yes No No 110 19.5 165 
84 Eswari Control 47 Female No Yes No 156 18.9 240 
85 Ganeshan Control 42 Male Yes No No 110 18.9 220 
86 Vasuki Control 35 Female No No No 116 22.4 160 
87 Prabakaran Control 56 Male No Yes No 125 22.4 260 
88 Rasathi Control 53 Female No No Yes 186 17.55 200 
89 Muniyammal Control 61 Female No No No 105 21.09 230 
90 Sundrammal Control 65 Female No No No 136 24.01 160 
91 Sivasami Control 62 Male Yes No No 156 20.27 255 
92 Arumugam Control 72 Male No Yes No 166 29.41 270 
93 Muniyasamy Control 61 Male No Yes Yes 184 24.01 345 
94 Natchimuthu Control 61 Male Yes Yes Yes 236 28.2 400 
95 Kannan Control 58 Male No No No 106 20.27 255 
96 Kaliyammal Control 53 Female No Yes No 184 21.64 325 
97 Karunakaran Control 52 Male No Yes No 166 22.4 240 
98 Muthaiyah Control 48 Male No No No 110 18.9 180 
99 Kumarasamy Control 45 Male Yes No No 145 21.09 205 
100 Sadaiyandi Control 39 Male Yes No No 86 23.2 215 
 
 
  
 
 
 
 
 
 
 
 
 
 
76%
24%
0%
20%
40%
60%
80%
Male Female
Incidences with Relation to Sex
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
SIGNIFICANT HISTORY
14%
60%
38%
54%
22%
0%
20%
40%
60%
80%
T1
A
Dia
be
tes
 
Hy
pe
rte
ns
ion
Sm
ok
ing IHD
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
384.4
260
-50
50
150
250
350
450
Cases Control
MEAN PLASMA FIBRINOGEN IN 
CASES Vs CONTROLS
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
431.3
355.7
300.6
239.1
0
100
200
300
400
500
Cases Controls 
HT AND PLASMA FIBRINOGEN
HT Non HT
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
435.5
307.8 320.5
212.5
0
150
300
450
600
Cases Controls
DM AND PLASMA FIBRINOGEN
Diabetes Non Diabetes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
384.5 384.2
275
210
0
100
200
300
400
500
Cases Controls
SEX AND PLASMA FIBRINOGEN
Male Female
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
345
18
7.
5
334.5
21
9.
1
382.2
27
7.
5
414.7
27
6.
8
440
31
1.
3
0
100
200
300
400
500
31-40 41-50 51-60 61-70 >70
AGE AND PLASMA FIBRINOGEN
Cases Controls
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
3
1
9
2
11
3
11
6
4
0
0
5
10
15
31-40 41-50 51-60 61-70 >71
INCIDENCE IN RELATION TO AGE
Male Female
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
338.9
283.9313.2 265.9
0
50
100
150
200
250
300
350
400
Cases Controls
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
349.5
441.3
242.1
370
0
200
400
600
Cases Controls
CHOLESTEROL AND PLASMA 
FIBRINOGEN
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
246.2
386.9
236.2
310.7
0
100
200
300
400
Cases Controls
BMI AND PLASMA FIBRINOGEN
 
SIGNIFICANT HISTORY
14%
60%
38%
54%
22%
0%
20%
40%
60%
80%
T1
A
Dia
be
tes
 
Hy
pe
rte
ns
ion
Sm
ok
ing IHD
384.4
260
-50
50
150
250
350
450
Cases Control
MEAN PLASMA FIBRINOGEN IN 
CASES Vs CONTROLS
431.3
355.7
300.6
239.1
0
50
100
150
200
250
300
350
400
450
Cases Controls 
HT AND PLASMA FIBRINOGEN
HT Non HT
435.5
307.8 320.5
212.5
0
150
300
450
600
Cases Controls
DM AND PLASMA FIBRINOGEN
Diabetes Non Diabetes 
384.5 384.2
275
210
0
100
200
300
400
500
Cases Controls
SEX AND PLASMA FIBRINOGEN
Male Female
345
1
8
7
.
5
334.5
2
1
9
.
1
382.2
2
7
7
.
5
414.7
2
7
6
.
8
440
3
1
1
.
3
0
100
200
300
400
500
31-40 41-50 51-60 61-70 >70
AGE AND PLASMA FIBRINOGEN
Cases Controls
31
9
2
11
3
11
6
4
0
0
2
4
6
8
10
12
31-40 41-50 51-60 61-70 >71
INCIDENCE IN RELATION TO AGE
Male Female
CT PICTURE OF INFARCTION  
 
  
 
 
 
ELECTRON MICROSCOPIC PICTURE PLASMA 
FIBRINOGEN 
 
 
 
 
 
 
 THE CIRCLE OF WILLIS 
 
 
     The circle of willis  
 
 
 
 
